This inaugural funding phase awarded two pioneering projects, each granted $50,000 to accelerate discovery efforts and therapeutic validation processes. These projects, helmed by senior investigative scientists at Massey and co-developed in partnership with SBP, underscore the vital integration of state-of-the-art biochemical screening methodologies and medicinal chemistry within academic research settings. By leveraging these cross-institutional synergies, the program seeks to fast-track the drug discovery pipeline from molecular target validation through to preclinical candidate nomination with unprecedented efficiency.

Dr. Robert A. Winn, the Director and Lipman Chair in Oncology at Massey, emphasizes that this collaborative venture inaugurates a novel epoch in translational cancer research. He highlights that the engagement with SBP’s world-renowned assay development and high-throughput compound screening capabilities equips Massey investigators with enhanced tools to expediently translate biological insights into precision oncology agents. This strategic alignment is anticipated to markedly shorten the temporal gap between laboratory breakthroughs and clinical application, addressing the urgent need for novel therapeutics targeting recalcitrant cancer phenotypes.

The two selected projects represent innovative molecular paradigms that target critical and previously underexplored pathways within cancer cells. The first project, titled “Targeting Hsp27-CerS1 Interaction in Solid Tumors,” is spearheaded by Dr. Can Senkal, whose expertise in cellular, molecular, and genetic medicine informs this endeavor. This project focuses on disrupting the interaction between Heat Shock Protein 27 (Hsp27) and Ceramide Synthase 1 (CerS1), a regulatory node implicated in tumor cell survival and apoptosis resistance. By intervening at this juncture, the project aims to destabilize cancer cell proteostasis and potentiate cell death mechanisms selectively within solid tumors.

Complementing this effort, the second project is under the leadership of Dr. Anthony Faber, who occupies the Natalie N. and John R. Congdon, Sr. Endowed Chair in Cancer Research. His work employs a sophisticated cell-based screening platform designed to identify ferroptosis-inducing compounds that impede selenocysteine incorporation. Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a promising vulnerability in malignancies resistant to classical apoptotic pathways. By targeting the unique mechanism of selenocysteine incorporation into essential selenoproteins, this approach could irreversibly compromise cancer cell antioxidant defenses and survival.

The integration of novel assay technologies with high-throughput screening paradigms at the Prebys Center for Drug Discovery provides the backbone for these endeavors. This center’s unique capacity for rapid assay development, coupled with robust medicinal chemistry programs, allows investigators to validate small molecules with clinical-grade rigor. Such infrastructure is critical for generating candidate compounds that meet the stringent requirements for advancement into clinical trials, while simultaneously furnishing comprehensive preliminary data packages for robust National Institutes of Health (NIH) and National Cancer Institute (NCI) grant submissions.

M2M’s overarching vision seamlessly aligns with precision medicine principles, aiming to bridge the translational gap by fostering multidisciplinary collaborations between basic researchers, pharmacologists, and medicinal chemists. The initiative’s operational leadership, including Dr. Said M. Sebti and Dr. Shamik Ghosh, acknowledges that this partnership enhances the breadth and depth of therapeutic discovery capabilities at VCU Massey. It introduces breakthrough assay modalities and industry-standard screening processes traditionally accessible only at dedicated drug discovery entities.

Furthermore, this trailblazing program is catalytic in nature, designed not only to identify new pharmacological agents but also to establish robust research pipelines that encourage sustained innovation and therapeutic exploration. By successfully marrying the scientific rigor of academia with the accelerated workflow standards of pharmaceutical discovery, this collaboration exemplifies a new model for addressing the perennial challenge of drug development in oncology. The resulting acceleration from bench to bedside promises to deliver novel therapies with greater efficiency and clinical relevance.

The focus on molecular targets such as the Hsp27-CerS1 axis and the ferroptosis pathway reflects a strategic investment in mechanistically nuanced approaches that exploit unique vulnerabilities within cancer cells. These strategies expand beyond conventional chemotherapy and targeted agents by addressing proteostasis and regulated cell death modalities that have hitherto been difficult to manipulate pharmacologically. This underscores a paradigm shift in drug discovery, wherein molecular precision and pathway selectivity are paramount to achieving therapeutic breakthroughs.

As this collaboration unfolds, it is expected that the resultant data sets and generated compounds will significantly contribute to the global oncology research landscape. Through comprehensive validation and iterative medicinal chemistry optimization at SBP, these projects lay the groundwork for clinical trials targeting solid tumors refractory to existing interventions. The merging of discovery science with translational application embodied in this partnership sets a laudable precedent for future academic-industry alliances aiming to combat cancer with innovative small-molecule therapeutics.

In sum, the VCU Massey and Sanford Burnham Prebys collaborative program is an emblematic initiative that redefines drug discovery within an academic framework. By converging advanced biochemical research with practical drug development methodologies, it facilitates a new frontier in cancer treatment innovation. The program not only accelerates the generation of promising therapeutic candidates but also galvanizes the research community to pursue bold hypotheses grounded in molecular oncology, propelling the field toward transformative patient outcomes.

Subject of Research: Novel small-molecule cancer therapeutics targeting Hsp27-CerS1 interaction and ferroptosis pathways.

Article Title: Advancing Cancer Therapy: VCU Massey and Sanford Burnham Prebys Collaborative Drug Discovery Initiative.

News Publication Date: April 8, 2026.

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/5b177769-fa05-4974-9e57-1693c81fff5c/Rendition/low-res/Content/Public

Image Credits: VCU Massey Comprehensive Cancer Center

Keywords: Drug discovery, Molecular targets, Cancer therapeutics, Small-molecule agents, Hsp27-CerS1 interaction, Ferroptosis, Selenocysteine incorporation, Translational oncology, High-throughput screening, Medicinal chemistry, Precision medicine, Solid tumors.

HPV, a ubiquitous virus infecting an estimated 80 million individuals in the United States alone, contributes directly to the pathogenesis of multiple malignancies, including oropharyngeal, cervical, anal, vaginal, vulvar, and penile cancers. Unlike many cancers characterized by complex etiologies, these HPV-related cancers share a unique preventive strategy enabled through prophylactic vaccination. HPV vaccines have demonstrated robust efficacy and safety profiles, both clinically and in real-world settings, offering long-lasting immunity that disrupts the viral oncogenic mechanism by targeting high-risk HPV strains responsible for oncogenesis.

Despite the availability and proven benefits of HPV vaccination, recent data from the National Immunization Survey-Teen reveal concerning stagnation in vaccination rates over recent years. This plateau signals an alarming deviation from expected public health trajectories and underscores systemic impediments in vaccination outreach and acceptance. An analysis of these trends emphasizes a critical window during early adolescence—particularly ages nine to twelve—where initiating the vaccine series aligns with optimal immunogenicity and long-term protection. The pressing need to reverse this stagnation is clear: ensuring that today’s youth receive timely vaccination is fundamental to curtailing the future incidence of HPV-driven cancers.

Central to the scientific community’s advocacy is the recognition that a subset of cancers, traditionally viewed through the lens of therapeutic interventions only, can be effectively eliminated through primary prevention. Although exceptions exist, HPV-associated malignancies present a paradigm shift, highlighting the remarkable power of vaccines not only to prevent infectious diseases but also to drastically mitigate cancer burden. The biological underpinning of this vaccine’s impact rests on its ability to elicit neutralizing antibodies against the L1 capsid protein of oncogenic HPV types, thus preventing viral entry and subsequent integration into the host genome—a key step in oncogenesis.

Importantly, cervical cancer stands out as a model disease demonstrating the full preventive potential of HPV vaccination. Studies led by gynecologic oncologists at Massey Comprehensive Cancer Center reveal that nearly all cervical cancer cases can be linked to persistent HPV infections. The vaccine’s safety profile and immunogenic efficacy have been corroborated through randomized controlled trials and extensive post-marketing surveillance. Indeed, vaccination programs initiated in multiple countries have already begun to show a decline in the prevalence of high-grade cervical lesions and HPV-associated cancers, validating predictions of near eradication if global vaccination uptake improves commensurately.

The call to action extends beyond the scientific and medical communities to involve a multi-tiered strategy incorporating healthcare systems, education, policy, and public awareness. Healthcare providers are urged to implement systematic identification and active outreach to patients eligible for HPV vaccination, reinforcing the essential message of cancer prevention through immunization. Concurrently, parent and caregiver engagement remains paramount, as informed decision-making directly influences vaccine acceptance and completion rates. The synergy between provider recommendations and familial consent will ultimately determine the success of vaccination initiatives.

Moreover, scientific advocates emphasize the necessity to demystify HPV vaccination through transparent communication that addresses common misconceptions and vaccine hesitancy. Misinformation regarding vaccine safety, purported side effects, or futility in vaccinating sexually inactive adolescents represents significant barriers that require evidence-based educational interventions. Utilizing authoritative resources from entities such as the Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), and the American Academy of Pediatrics (AAP) provides accessible, reliable information critical to shifting public perception and fostering vaccine confidence.

Notably, the extensive coalition endorsing this statement includes a diverse range of NCI-Designated Cancer Centers spanning academic institutions, research hospitals, and comprehensive medical centers across the nation. This consensus among preeminent cancer research entities signals an unprecedented unified front supporting HPV vaccination as a cornerstone of cancer control strategies. Their endorsement amplifies the message’s authority, supporting dissemination efforts at national, state, and local levels.

Parallel to cancer centers, national organizations such as the American Association for Cancer Research, the American Society of Clinical Oncology, and the Prevent Cancer Foundation, among others, have lent their voices to this campaign. Their collective expertise and outreach capacity ensure comprehensive coverage of clinical, preventive, and public health dimensions concerning HPV vaccination uptake and education. Inclusion of patient advocacy groups like Cervivor underscores the patient-centric approach to this public health initiative, recognizing the importance of lived experience narratives in shaping societal attitudes toward vaccination.

From a scientific perspective, advancing HPV vaccine coverage not only promises a significant reduction in cancer incidence but also offers economic benefits by decreasing long-term treatment costs and mitigating productivity losses associated with cancer morbidity. Analytical models considering herd immunity effects suggest that achieving high vaccine coverage could precipitate near-elimination of HPV-related cancers in forthcoming decades. Consequently, HPV vaccination represents a striking example of precision public health—where targeted intervention based on molecular epidemiology offers scalable impact at the population level.

This momentous joint statement coincides strategically with back-to-school vaccination schedules and the observance of Gynecologic Cancer Awareness Month, thereby capitalizing on temporal alignment to maximize public engagement. Increasing vaccination rates during early adolescence, when immunologic responses to the HPV vaccine are most robust, aligns with epidemiological data indicating pre-exposure immunization confers optimal protection. The ongoing challenge lies in bridging clinical evidence and implementation frameworks to ensure equitable vaccine access, particularly among underserved populations disproportionately burdened by HPV-related cancers.

In conclusion, the exhortation from VCU Massey Comprehensive Cancer Center and its esteemed partners illustrates a groundbreaking commitment to leveraging HPV vaccination as a public health imperative. Their direct appeal to healthcare systems, providers, parents, and communities encapsulates a paradigm shift towards cancer prevention grounded in scientific innovation and collaborative action. Harnessing the full potential of HPV immunization stands as a transformative opportunity to reduce cancer incidence, alleviate healthcare disparities, and ultimately save thousands of lives annually.

Subject of Research: People

Article Title: Joint Statement Endorsing HPV Vaccination for Cancer Prevention by National Cancer Institute-Designated Centers

News Publication Date: September 25, 2025

Web References:

• National Cancer Institute (NCI) Cancer Centers: https://www.cancer.gov/research/infrastructure/cancer-centers
• CDC National Immunization Survey-Teen Data: https://www.cdc.gov/mmwr/volumes/74/wr/mm7430a1.htm?s_cid=OS_mm7430a1_w
• CDC HPV Vaccination Information: https://www.cdc.gov/hpv/vaccines/index.html
• American Cancer Society HPV Vaccine Information: https://www.cancer.org/cancer/risk-prevention/hpv/hpv-vaccine.html
• ACS National HPV Vaccination Roundtable: https://hpvroundtable.org/
• American Academy of Pediatrics Immunization Schedule: https://www.healthychildren.org/English/safety-prevention/immunizations/Pages/Recommended-Immunization-Schedules.aspx

Keywords: Vaccine research, HPV vaccination, cancer prevention, public health, immunization, National Cancer Institute, HPV-related cancers, adolescence, tumor immunology